Testing shows that it is a suitable compound for prophylaxis for those that suffer from chronic vulvovaginal candidiasis.

It works as a broad spectrum antifungal and has shown to be an effective first-line treatment against other Candida species.

This study focused on the drug as an 80 mg vaginal suppository, taken three times overnight by 10 women.

[4] In another placebo-controlled, double blind study by Schmidt et al., the efficacy of different concentrations of terconazole creams were tested.

[6] The most common side effects of terconazole include headaches, vulvar/vaginal irritation, rash, itching, burning or discomfort.

[7] Other side effects may include abdominal pain or cramps, dysmenorrhea, chills, fever and allergic reactions.

[citation needed] Terconazole synthesis synologous with ketoconazole except for the fact that triazole and not imidazole heterocyclic ring is used, and that isopropyl group instead of acetamide.

These are put in a solution and catalyzed using dimethyl sulfate at 1300 °C (2372 °F) to give many different types of triazole derivatives.

Metabolism is extensive and is highly protein bound (94.9%) with the degree of binding being independent of drug concentration.

[19] In 1940, the first commercial antifungal drug, called amphotericin B, was available on the market, replacing rare and expensive treatments.

The first azole compounds to replace this treatment were synthesized in the late 1960s and early 1970s and administered to humans under strict care.

Triazole based drugs came shortly after and quickly gained popularity due to its broader spectrum of antifungal activity and less toxicity.

[21] Previously, all triazole based drugs targeted fungal infections related to plants from Candida species.

Since creation, terconazole has been superseded by second-generation triazoles due to their even broader spectrum and higher activity levels against resistant pathogens like Aspergillus spp.